Drug discovery

#Drug discovery #Drug innovation #ELRIG #Events #Innovation

ELRIG UK’s Drug Discovery 2021 

Given the unexpected couple of years we have had as a result of the Covid-19 pandemic, the drug discovery sector is no doubt looking forward to an in-person event at last. ELRIG UK’s Drug Discovery 2021 will take place at the ACC, Liverpool, UK on 19-20 October.  DDW has teamed up with ELRIG UK to produce… Read More

#Editor's Choice #News

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News

#Biologics / Biotechnology #Cell painting #Collaboration #Drug discovery #Phenomics #Podcast

Recipe for success: collaboration in drug discovery – podcast 

The latest free-to-listen DDW podcast episode is titled “Recipe for success: collaboration in drug discovery”. It covers three articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas.  These articles are titled: “Why collaboration matters and… Read More

#Editor's Choice #News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Deriving context from immunological data with flow cytometry – Webinar

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA

AstraZeneca collaboration to develop RNA therapeutics  

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More

#News

#Cancer immunotherapy #Cancer research #Drug discovery #Immuno-oncology #Systems biology #Therapeutics #Webinar

Event examines emerging strategy for cancer therapeutic development 

In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).  Challenges and Opportunities in Protein Degradation, took place on… Read More

#News

#Antivirals #Covid-19 #Drug discovery

Covid-19 antiviral pill cuts hospitalisation and deaths in half

If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News

#Collaboration #Drug development #Drug discovery #Life sciences

Brooks introduces Azenta Life Sciences to advance sample solutions 

Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences. Azenta will bring together Brookes’ existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions.  “We are excited to announce the creation of Azenta as… Read More

#News

#Collaboration #Drug discovery #ELRIG #Research

Equality, diversity and inclusion at Drug Discovery 2021

The European Laboratory Research & Innovation Group (ELRIG) UK will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Drug development #Drug discovery #Microbiome #Podcast #Precision medicine

Podcast: Opportunities to improve drug discovery systems

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release… Read More

#News #Trending News